Letrozole-matched Placebo
Phase 3
RocheLetrozole-matched Placebo is one of 4 therapeutic programs targeting Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[2][1]
Indication
Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerActive, not recruiting
Active, not recruiting
Competition
Competitive Landscape
3 competitors in Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
#DrugCompanyPhaseTrials
1Ibrance
PfizerPhase 3
Giredestrant
RochePhase 3
LHRH Agonist
RochePhase 3
Letrozole-matched Placebo
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Letrozole-matched Placebo. EMBL-EBI & Wellcome Sanger Institute.
- [3]